查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
癌症诊断领域人工智慧的全球市场：预测（2023-2028）
市场调查报告书
商品编码
1410108

癌症诊断领域人工智慧的全球市场：预测（2023-2028）

AI in Cancer Diagnostics Market - Forecasts from 2023 to 2028
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 147 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

2021年全球癌症诊断人工智慧市场规模达807,795,000美元。

随着人工智慧技术彻底改变癌症诊断，癌症诊断的人工智慧市场正在迅速扩大。人工智慧演算法分析大量患者资料，包括医学照片、遗传资料和临床记录，以帮助识别、分类和预测癌症。利用机器学习和深度学习方法，人工智慧系统可以发现医学照片中的微妙模式和异常，从而早期发现癌症并改善患者预后。人工智慧在癌症诊断中的整合可以提高准确性、消除诊断错误并提供个体化的治疗方法建议。随着癌症盛行率的不断上升，以及对高效、准确诊断解决方案的需求不断增长，人工智慧在癌症诊断市场中将在彻底改变癌症治疗和推动精准医疗进步方面发挥巨大作用，前景广阔。

人工智慧技术的进步将加强人工智慧在癌症诊断市场的成长。

人工智慧的发展有可能透过提高准确性、效率和早期检测率来彻底改变癌症诊断，最终改善患者的治疗结果和个体化治疗方法。

多模态资料集成，用于癌症诊断市场人工智慧的综合分析。

整合多模式资料进行彻底分析已成为癌症诊断的重大发展。整合多模式资料可以更详细地了解疾病，使医生能够做出明智的决策并为癌症患者制定个体化的治疗策略。

改善患者治疗效果和治疗计划将推动人工智慧在癌症诊断市场的规模。

改善患者治疗效果和治疗计画是将人工智慧纳入癌症诊断的两大好处。根据发表在 JAMA Network Open 上的一项研究，与人类病理学家相比，人工智慧演算法提高了肺癌检测的准确性，从而改善了患者的治疗结果。这项研究发现人工智慧辅助诊断提高了敏感性和特异性。此外，根据《自然医学》发表的一项研究，基于人工智慧的乳癌治疗计划模型显着减少了不必要的手术，从而改善了患者的治疗结果和生活品质。这些发现表明人工智慧 (AI) 可以指导治疗决策、优化药物选择并减少治疗浪费，从而改善患者治疗效果并创造更个体化和有效的癌症治疗方法。我们强调我们提供的可能性。

北美是癌症诊断人工智慧市场的市场领导者。

北美已成为癌症诊断市场人工智慧的行业领导者。该地区的主导地位有几个原因。北美拥有先进的医疗基础设施、许多主要的人工智慧企业，并且高度重视癌症研究和开发。此外，该地区受益于医疗机构、研究中心和技术公司之间的紧密联繫，这促进了创新并推动了基于人工智慧的癌症诊断的发展。此外，北美拥有完善的法律规范，可以轻鬆在医疗保健领域引入和使用人工智慧技术。此外，该地区庞大的患者群体、高昂的医疗成本以及优惠的报销规则都促进了该地区人工智慧在癌症诊断市场的成长。然而，随着欧洲和亚太地区等其他地区在癌症诊断市场的人工智慧方面继续取得重大进展，密切关注不断变化的环境非常重要。

人工智慧在癌症诊断市场中越来越多地采用数位病理学和放射学。

在人工智慧癌症诊断领域，数位病理学和放射学的使用显着增加。数位病理学测试将病理切片数位化，从而可以轻鬆存取、共用和分析高解析度影像。好处包括远端协作、更好的影像处理以及与人工智慧演算法的无缝整合。同样，数位放射线可以实现医学影像的数位化，从而实现更快、更有效率的影像储存、搜寻和分析。数位病理学和数数位放射线的广泛应用将为人工智慧技术在癌症诊断中的应用奠定坚实的基础。实现更准确、更有效率的诊断、分类和治疗计划，从而实现更精准、个体化的癌症治疗。数位病理学和放射学与人工智慧的融合具有彻底改变癌症诊断的巨大潜力。

主要进展：

2023年7月，人工智慧和精准医疗领域的先驱Tempus与TScan Therapeutics合作，TScan Therapeutics是一家临床阶段的生物製药公司，专注于为癌症患者开发TCR工程化T细胞疗法（TCR-T）。伴同性诊断(CDx) 测试。该合作伙伴关係将支持 TScan 的 1 期固体癌临床试验筛检程序，使患者能够接受基于肿瘤抗原阳性和完整 HLA 表达的客製化 TCR-T 组合。 2023 年 6 月，着名的病理诊断人工智慧 (AI) 供应商 Mindpeak 和领先的数位病理学和计算病理学解决方案提供商 Proscia 宣布，他们将为癌症患者提供先进的诊断服务。改善透过此次合作，两家公司正在为紧密整合的人工智慧驱动流程奠定基础，以帮助病理学家做出更有效率、更明智和可重复的临床选择。

企业产品

  • Watson for Oncology：这个人工智慧驱动的系统使用自然语言处理和机器学习技术来帮助肿瘤学家做出明智的治疗决策。我们分析病历、研究论文和临床指引等患者资料，以提案适合每位患者需求的实证治疗方法。
  • NVIDIA DGX 系统：研究人员和医疗保健相关人员可以使用这个先进的 AI 计算平台来训练和部署用于癌症诊断的复杂 AI 模型。 DGX 设备提供更快的运算能力，使建立用于癌症诊断的 AI 演算法和应用程式变得更加容易。
  • Tempus 临床平台：此平台收集并分析来自资料来源的大量临床和分子资料，包括电子健康记录、病理报告、基因组定序和放射影像。 Tempus 的人工智慧演算法从这些资料中提取相关见解，以帮助癌症诊断、治疗计划和预后预测。
  • Concentriq Dx：此数位病理平台使用人工智慧演算法来改进病理影像的处理和解释。实现自动影像处理，例如肿瘤检测、恶性确定和定量。该工具透过实现数位载玻片的快速检查和註释来促进病理学家的协作。

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表

第二章调查方法

  • 调查资料
  • 资讯来源
  • 研究设计

第三章执行摘要

  • 研究亮点

第四章市场动态

  • 市场驱动因素
  • 市场抑制因素
  • 波特五力分析
    • 供应商的议价能力
    • 买方议价能力
    • 新进入者的威胁
    • 替代品的威胁
    • 业内竞争对手之间的对抗关係
  • 产业价值链分析

第五章癌症诊断中的人工智慧市场：按癌症类型

  • 介绍
  • 乳癌
  • 肺癌
  • 摄护腺癌
  • 大肠直肠癌
  • 皮肤癌
  • 其他的

第六章癌症诊断中的人工智慧市场：按应用分类

  • 介绍
  • 肿瘤检测与分类
  • 治疗计划
  • 影像分析
  • 基因组分析
  • 其他的

第七章癌症诊断中的人工智慧市场：按最终用户划分

  • 介绍
  • 医院/诊所
  • 诊断中心
  • 研究机构
  • 其他的

第八章癌症诊断中的人工智慧市场：按地区划分

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 英国
    • 德国
    • 法国
    • 义大利
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 韩国
    • 印尼
    • 台湾
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 供应商竞争力矩阵

第十章 公司简介

  • GOOGLE LLC（ALPHABET INC.）
  • IBM CORPORATION
  • MICROSOFT CORPORATION
  • PAIGE.AI, INC.
  • TEMPUS LABS, INC.
  • PATHAI, INC.
  • INSPIRATA, INC.
  • PROSCIA INC.
  • IBEX MEDICAL ANALYTICS LTD.
  • ZEBRA MEDICAL VISION LTD.
简介目录
Product Code: KSI061615774

The AI in cancer diagnostics market was valued at US$807.795 million in 2021.

The AI in the cancer diagnostics market is expanding rapidly as artificial intelligence technologies revolutionise cancer diagnostics. AI algorithms analyse massive volumes of patient data, such as medical pictures, genetic data, and clinical records, to help in the identification, classification, and prognosis of cancer. AI systems can discover subtle patterns and anomalies in medical pictures using machine learning and deep learning approaches, resulting in early cancer identification and improved patient outcomes. AI integration in cancer diagnostics can improve precision, eliminate diagnostic mistakes, and provide personalised therapy recommendations. With the rising prevalence of cancer and the increasing demand for efficient and accurate diagnostic solutions, AI in the cancer diagnostics market offers enormous promise for revolutionising cancer care and propelling advances in precision medicine.

Advancements in Artificial Intelligence Technologies Enhance the AI in Cancer Diagnostics Market Growth.

AI developments have the potential to revolutionise cancer diagnostics by increasing accuracy, efficiency, and early detection rates, ultimately leading to better patient outcomes and personalised treatment methods.

Integration of Multi-modal Data for Comprehensive Analysis in AI in Cancer Diagnostics Market.

Integrating multimodal data for thorough analysis has emerged as a key development in cancer diagnoses. The integration of multimodal data enables a more thorough picture of the disease, allowing doctors to make educated decisions and design personalised treatment strategies for cancer patients.

Improved Patient Outcomes and Treatment Planning boosts the AI in Cancer Diagnostics Market Size.

Improved patient outcomes and treatment planning are two major benefits of incorporating AI in cancer diagnoses. Research published in JAMA Network Open found that AI algorithms enhanced lung cancer detection accuracy when compared to human pathologists alone, resulting in better patient outcomes. The study found that AI-assisted diagnosis improved in terms of both sensitivity and specificity. Furthermore, according to a study published in Nature Medicine, AI-based models for breast cancer treatment planning resulted in a considerable reduction in needless procedures, resulting in improved patient outcomes and quality of life. These findings emphasise the potential of artificial intelligence (AI) in guiding treatment decisions, optimising drug selection, and reducing needless treatments, thereby improving patient outcomes and providing more personalised and effective cancer care.

North America is the Market Leader in the AI in Cancer Diagnostics Market.

North America has established itself as the industry leader in AI in the cancer diagnostics market. Several reasons contribute to the region's prominence. North America has sophisticated healthcare infrastructure, a large presence of major AI businesses, and a strong emphasis on cancer research and development. Furthermore, the region benefits from substantial connections among healthcare institutions, research centres, and technology businesses, which fosters innovation and propels developments in AI-based cancer diagnoses. North America also has a favourable regulatory framework, making it easier to adopt and use AI technology in healthcare. Furthermore, the region's huge patient population, high healthcare spending, and favourable reimbursement rules all contribute to the region's AI in cancer diagnostics market growth. However, as other areas, such as Europe and Asia-Pacific, continue to make substantial advancements in the AI in cancer diagnostics market, it is critical to watch the developing environment.

Increasing Adoption of Digital Pathology and Radiology in AI in Cancer Diagnostics Market.

In the field of AI in cancer diagnoses, the use of digital pathology and radiology has seen a substantial increase. Pathology slides are digitised in digital pathology, providing for simple access, sharing, and analysis of high-resolution pictures. Remote collaboration, better picture processing, and seamless integration with AI algorithms are some of the advantages. Similarly, digital radiology allows for the digitalization of medical imaging, allowing for faster and more efficient picture storage, retrieval, and analysis. The growing use of digital pathology and radiology lays a solid platform for the use of AI technology in cancer diagnoses. It enables more precise and personalised cancer care by allowing for more accurate and efficient diagnosis, classification, and therapy planning. The merging of digital pathology and radiology with AI has enormous promise to revolutionise cancer diagnoses.

Key Developments:

  • In July 2023, Tempus, a pioneer in artificial intelligence and precision medicine, announced a new collaboration to develop a companion diagnostic (CDx) test with TScan Therapeutics, a clinical-stage biopharmaceutical company focused on the development of TCR-engineered T cell therapies (TCR-T) for cancer patients. The partnership supports TScan's screening procedure for its Phase 1 solid tumour clinical trial, which is meant to allow patients to receive customized TCR-T mixes based on tumour antigen positivity and intact HLA expression.
  • In June 2023, Mindpeak, a prominent supplier of artificial intelligence (AI) for pathology, and Proscia, a leading provider of digital and computational pathology solutions, announced a collaboration to increase cancer patients' access to enhanced diagnostics. The cooperation lays the groundwork for the firms to create tightly integrated AI-powered processes that enable pathologists to make more efficient, informed, and repeatable clinical choices.

Company Products:

  • Watson for Oncology: This artificial intelligence-powered system uses natural language processing and machine learning techniques to help oncologists make educated treatment decisions. It analyses patient data, such as medical records, research articles, and clinical guidelines, to produce evidence-based therapy suggestions tailored to each patient's specific needs.
  • NVIDIA DGX Systems: Researchers and healthcare practitioners may use these sophisticated AI computing platforms to train and deploy complicated AI models for cancer diagnoses. The DGX devices offer faster computational capabilities, making it easier to construct AI algorithms and apps for cancer diagnostics.
  • Tempus Clinical Platform: This platform collects and analyses massive volumes of clinical and molecular data from a variety of sources, such as electronic health records, pathology reports, genomic sequencing, and radiology images. Tempus' AI algorithms extract relevant insights from this data to help with cancer diagnosis, treatment planning, and prognosis prediction.
  • Concentriq Dx: This digital pathology platform uses AI algorithms to improve pathology picture processing and interpretation. It enables automatic image processing for activities including tumour detection, grading, and quantification. The tool promotes pathologist collaboration by allowing for the rapid inspection and annotation of digital slides.

Segmentation:

By Cancer Type

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Colorectal Cancer
  • Skin Cancer
  • Others

By Application

  • Tumor Detection And Classification
  • Treatment Planning
  • Image Analysis
  • Genomic Analysis
  • Others

By End-User

  • Hospitals And Clinics
  • Diagnostic Centers
  • Research Institutes
  • Others

By Geography

  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • United Kingdom
  • Germany
  • France
  • Italy
  • Spain
  • Others
  • Middle East And Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • Japan
  • China
  • India
  • South Korea
  • Indonesia
  • Taiwan
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base, and Forecast Years Timeline

2. RESEARCH METHODOLOGY

  • 2.1. Research Data
  • 2.2. Sources
  • 2.3. Research Design

3. EXECUTIVE SUMMARY

  • 3.1. Research Highlights

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porters Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. AI IN CANCER DIAGNOSTICS MARKET, BY CANCER TYPE

  • 5.1. Introduction
  • 5.2. BREAST CANCER
  • 5.3. LUNG CANCER
  • 5.4. PROSTATE CANCER
  • 5.5. COLORECTAL CANCER
  • 5.6. SKIN CANCER
  • 5.7. OTHERS

6. AI IN CANCER DIAGNOSTICS MARKET, BY APPLICATION

  • 6.1. Introduction
  • 6.2. TUMOR DETECTION AND CLASSIFICATION
  • 6.3. TREATMENT PLANNING
  • 6.4. IMAGE ANALYSIS
  • 6.5. GENOMIC ANALYSIS
  • 6.6. OTHERS

7. AI IN CANCER DIAGNOSTICS MARKET, BY END-USER

  • 7.1. Introduction
  • 7.2. HOSPITALS AND CLINICS
  • 7.3. DIAGNOSTIC CENTERS
  • 7.4. RESEARCH INSTITUTES
  • 7.5. OTHERS

8. AI IN CANCER DIAGNOSTICS MARKET, BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. United States
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. United Kingdom
    • 8.4.2. Germany
    • 8.4.3. France
    • 8.4.4. Italy
    • 8.4.5. Spain
    • 8.4.6. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. Japan
    • 8.6.2. China
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Taiwan
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Vendor Competitiveness Matrix

10. COMPANY PROFILES

  • 10.1. GOOGLE LLC (ALPHABET INC.)
  • 10.2. IBM CORPORATION
  • 10.3. MICROSOFT CORPORATION
  • 10.4. PAIGE.AI, INC.
  • 10.5. TEMPUS LABS, INC.
  • 10.6. PATHAI, INC.
  • 10.7. INSPIRATA, INC.
  • 10.8. PROSCIA INC.
  • 10.9. IBEX MEDICAL ANALYTICS LTD.
  • 10.10. ZEBRA MEDICAL VISION LTD.